The sample was investigated further.The ft4 iii and ft3 iii results (both at the customer site and during the preliminary investigation) were confirmed.The investigation confirmed, the presence of an interfering factor against the chemical ruthenium label structure of the assay.This specific interference is addressed in product labeling: in rare cases, interference, due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur.These effects are minimized by suitable test design.For diagnostic purposes, the results should always be assessed in conjunction with the patient¿s medical history, clinical examination and other findings.The investigation did not identify a product problem.
|